Share Option Grant

PuriCore plc

 ("PuriCore" or the "Company")

12 August 2013

Share Option Grant

PuriCore (LSE: PURI), a global company focused on safely and effectively protecting people from the spread of infectious pathogens, announces today a share option grant, in accordance with the Disclosure and Transparency Rules. On 9 August, PuriCore issued share options to a Company Independent Non-Executive Director as set forth below. The share options have an exercise price of 41.0p, which is the closing market price of the Company's ordinary shares on 9 August 2013, and a five-year term.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, both Sterilox Fresh and FloraFresh provide savings to supermarket retailers in labour costs and improvements in inventory loss of fresh produce and floral products. In addition, the Company is progressing in its research and development programmes at Oxford University on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.